Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/1733| Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2 | |
| Jonathan Hon Kwan Chen Cyril Chik-Yan Yip Rosana Wing-Shan Poon Kwok Hung Chan Ivan Fan Ngai Hung Jasper Fuk-Woo Chan Kwok_yung Yuen | |
| Acceso Abierto | |
| Atribución | |
| https://doi.org/10.1080/22221751.2020.1775133 | |
| SARS-CoV-2 Saliva Nasopharyngeal swab Point-of-care testing | |
| During the Coronavirus disease 2019 (COVID-19) pandemic, logistic problems associated with specimen collection limited the SARS-CoV -2 testing especially in the community. In this study, we assessed the use of posterior oropharyngeal saliva as specimens for the detection of SARS-CoV -2 in an automated point-of-care molecular assay. Archived nasopharyngeal swab (NPS) and posterior oropharyngeal saliva specimens of 58 COVID-19 patients were tested with the Xpert® Xpress SARS-CoV -2 assay . SARS -CoV -2 was detected in either NPS or saliva specimens of all patients. Among them, 84.5% (49/58) tested positive in both NPS and saliva, 10.3% (6/58) tested positive in NPS only, and 5.2% (3/58) tested positive in saliva only. No significant difference in detection rate was observed between NPS and saliva (McNemar’s test p=0.5078). The detection rate was slightly higher for N2 (NPS 94.8% and Saliva 93.1%) than that of the E gene target (Saliva:89.7% vs 82.8%) on both specimen types. Significant earlier median Ct value was observed for NPS comparing to that of saliva on both E (26.8 vs 29.7, p=0.0002) and N2 gene target (29.3 vs 32.3, p=0.0002). The median Ct value of E gene target was significantly earlier than that of the N2 gene target for both NPS (26.8 vs 29.3, p<0.0001) and saliva (29.7 vs 32.3, p<0.0001). In conclusion, posterior oropharyngeal saliva and NPS were found to have similar detection rates in the point-of-care test for SARS-CoV-2 detection. Due to the easy collection of posterior oropharyngeal saliva, the use of saliva as an alternative specimen type for SARS-CoV-2 detection is recommended | |
| Emerging Microbes & Infections | |
| 2020 | |
| Preimpreso | |
| https://www.tandfonline.com/action/showCopyRight?scroll=top&doi=10.1080%2F22221751.2020.1775133 | |
| Inglés | |
| Epidemia COVID-19 | |
| Investigadores | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2.pdf | 489.67 kB | Adobe PDF | Visualizar/Abrir |